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Spatial and temporal dissection of the genomic changes occurring during the 
evolution of human non-small cell lung cancer (NSCLC)  may help elucidate the basis 
for its dismal prognosis. We sequenced 25 spatially distinct regions from seven 
operable NSCLCs  and found evidence of  branched evolution, with driver mutations 
arising before and after subclonal diversification. There was pronounced intra-tumor 
heterogeneity in copy number alterations, translocations, and mutations associated 
with APOBEC cytidine deaminase activity. Despite maintained carcinogen exposure, 
tumors from smokers showed a relative decrease in smoking-related mutations over 
time, accompanied by an increase in APOBEC-associated mutations. In tumors from 
ex-smokers, genome-doubling occurred within a smoking-signature context before 
subclonal diversification, suggesting that a long  period of tumor latency had preceded 
clinical detection. The regionally separated driver mutations, coupled with the 
relentless and heterogeneous nature of the genome instability processes are likely to 
confound treatment success in NSCLC. 
Main Text:  
Lung cancer is the leading cause of cancer-related mortality (1, 2). 
Understanding the pathogenesis and evolution of lung cancer may lead to greater 
insight into tumor initiation and maintenance, and guide therapeutic interventions. 
Previous work characterizing the genome of non-small cell lung cancer (NSCLC) has 
demonstrated that NSCLC genomes exhibit hundreds of non-silent mutations together 
with copy number aberrations and genome doublings (3-9). Although subclonal 
populations have been identified within single biopsies (9), the extent of genomic 
diversity within primary NSCLCs remains unclear. Moreover, while both exogenous 
mutational processes, such as smoking (10-12) and endogenous processes, such as up-
regulation of APOBEC cytidine deaminases (13-15), have been found to contribute to 
the large mutational burden in NSCLC, the temporal dynamics of these processes and 
their contribution to driver somatic aberrations over time remains unknown.  
To investigate lung cancer evolution, we performed multi-region whole-
exome and/or whole-genome sequencing (M-seq WES/WGS) on a total of 25 tumor 
regions, collected from seven NSCLC patients who underwent surgical resection prior 
to receiving adjuvant therapy. The major NSCLC histological subtypes, including 
adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), were represented 
(table S1). Sequencing of tumor and normal DNA to mean coverage depths of 107x 
and 54x for M-WES and M-WGS respectively (table S2), identified 1884 non-silent 
and 76,129 silent mutations (16). 
To evaluate the intra-tumor heterogeneity of non-silent mutations, we 
classified each mutation as ubiquitous (present in all tumor regions) or heterogeneous 
(present in at least one, but not all regions). Spatial intra-tumor heterogeneity was 
identified in all seven NSCLCs with a median of 30% heterogeneous mutations 
(range 4-63%, Fig. 1A and fig. S1). In the adenosquamous tumor L002, 
heterogeneous mutations separated concordant with LUAD (regions R1-R2) or LUSC 
(regions R3-R4) histopathologies (Fig. S2). Patients L003 and L008 each presented 
with two tumors in separate lobes of the lung. Whilst M-seq WES revealed 74% 
ubiquitous mutations in L008, only a single mutation (EGFRL858R) was detected in 
both tumors for L003 (Fig. 1A). Given that EGFRL858R is a highly recurrent mutation 
(17) and also that no silent mutations were shared, we conclude these tumors were of 
independent clonal origin, converging upon identical oncogenic events. 
To resolve the extent of genomic diversity in NSCLC and infer the ancestral 
relationships between tumor regions, we estimated the proportion of tumor cells 
within each region harboring each mutation (16, 18).  Almost all ubiquitous mutations 
(>99%) were classified as fully clonal within each region. Moreover, in most regions, 
the majority of heterogeneous/branched mutations were clonal and thus present in all 
cells within the region (Figs. 1B and fig. S3). However, certain regions displayed 
considerable subclonal diversity. For example, >75% of heterogeneous mutations 
present in L004 R5 were subclonal and this region consisted of two distinct subclonal 
populations  (Fig 1B). The subclonal structure of each tumor region was then used to 
construct phylogenetic trees, using both Maximum Parsimony and the Unweighted 
Pair Group Methods (UPGMA), and also accounting for regional copy number losses 
resulting in shared truncal mutations becoming private to one region (16) (fig. S4). 
Notably, all seven NSCLCs showed evidence of branched tumor evolution (fig. S5).   
We next evaluated the regional heterogeneity of potential NSCLC driver 
mutations, classified into three categories based on current evidence supporting driver 
mutation status (16). Every tumor showed evidence for ubiquitous as well as 
heterogeneous driver mutations, many of which were clonally dominant in a subset of 
tumor regions while entirely absent in others (Fig. 1B, fig. S3 and table S3). 
Importantly, the probability of missing a category 1 “high confidence” driver gene by 
analyzing a single region for each tumor was on average 42% (range 0-67%), and 
83% (range 67-100%) for all potential driver genes (category 1-3), highlighting the 
potential limitations of single-biopsy approaches. Nevertheless, category 1-2 driver 
mutations were significantly more often truncal compared to mutations in non-driver 
genes in our M-seq analysis (P=0.04). Consistent with these data, in the TCGA cohort 
previously reported driver genes (5, 19, 20) were significantly enriched for clonal 
mutations (fig. S6, P<0.001). These data indicate that in NSCLC most known driver 
mutations occur early in tumor evolution. 
To determine the intra-tumor heterogeneity of copy number aberrations, we 
estimated integer DNA copy numbers for each tumor region (7, 16, 21, 22). A large 
fraction of the genome had undergone alterations in all tumors, and genomic profiles 
were more similar within tumors than between different tumors (fig. S7). To evaluate 
the spatial heterogeneity of potential tumor driver copy number aberrations, we 
explored the regional distribution of chromosomal segments identified as recurrently 
gained or lost in TCGA LUAD or LUSC tumors. Most segments were identified as 
aberrant in at least one tumor region and many recurrent gains and losses were found 
to be heterogeneous in at least one tumor (Fig 2A). For example, in L001, a focal 
EGFR amplification as well as deletions of chromosomal segments harboring 
CDKN2A and PTEN was observed in all regions, whereas in L008 we observed 
heterogenous copy number losses involving CDKN2A and PTEN.  In support of copy 
number aberrations occurring later in tumor development, we also identified 
subclonal copy number aberrations within tumor regions. For instance, over 15% of 
the genome in region R1 of L008 was subject to subclonal copy number alterations 
(fig. S8). Consistent with evidence of subclonal copy number aberrations, centromeric 
FISH analyses confirmed numerical chromosomal diversity within individual tumor 
regions (fig. S9), suggesting chromosomal instability may provide a substrate for 
subclonal competition.  
The high coverage M-seq WGS (mean 96x) for L002 and L008 enabled us to 
investigate the regional separation of large-scale genomic events in these samples. For 
the adenosquamous tumor L002, we identified 30 structural variants, most of which 
were found either in the LUAD region R1 or the LUSC region R3 but not both (table 
S4), suggesting they occurred after diversification into two distinct histological 
subtypes (Fig. 2B). By contrast, for L008, 48 of the 52 identified structural variants 
were shared between the two tumor regions from different lobes of the lung (Fig 2B). 
Intriguingly, in L008 “chains” of translocations with highly clustered breakpoints 
were found between chromosomes 14 and 17 as well as chromosomes 17 and 19 (fig. 
S10 and table S4), disrupting the FANCM and NF1 tumor suppressor genes. 
Breakpoint homology profiling suggests involvement of either non-homologous or 
alternative end-joining (23, 24), indicative of double-strand break events. This lesion 
pattern is consistent with chromoanagenesis (25), and indicates a punctuated 
evolution pattern where multiple oncogenic events may occur simultaneously (26). 
Four tumors displayed evidence for whole genome-doubling events (16). In 
three tumors (L001, L004, and L008), the genome-doubling event was shared across 
every tumor region, occurring prior to diversification with the majority of truncal 
mutations (84-88%) present at ploidy ≥2, indicative of a large mutational burden prior 
to genome doubling. In one tumor, L002, the majority of heterogeneous mutations 
were also present at ploidy ≥2, indicative of two independent genome-doubling 
events, one in the LUAD region and one in the LUSC region (fig. S11). Notably, 
every truncal driver mutation likely occurred prior to genome doubling.  
To further explore the dynamics of the mutational processes shaping lung 
cancer genomes over time, the spectra of point mutations in each tumor were 
temporally dissected. Early (truncal) mutations likely reflect processes involved prior 
to and during tumor initiation and early development, while late (branched) mutations 
reveal mutational processes shaping the genome during tumor maintenance and 
progression, including those contributing to intra-tumor heterogeneity. For L002 we 
analyzed regions R1 and R3 separately allowing comparisons of LUAD and LUSC 
histologies within the same tumor.  
In all tumors we observed statistically significant shifts in the mutation spectra 
over time (Fig. 3A; P<0.05 all cases). Furthermore, every tumor exhibited a 
statistically significant decrease in the proportion of C>A transversions in late 
compared to early mutations (Fig. 3A, P<0.05), although this was more pronounced 
in the LUAD cases (mean odds ratio: LUAD 3.13 (range 2.07-5.55), LUSC 1.34 
(range 1.21-1.46)).  Since C>A transversions are associated with the mutagenic 
effects of tobacco smoke (12), a decrease in the proportion of C>A transversions 
indicates a relative decrease in the mutational burden attributable to smoking during 
LUAD development, in both ex-smokers and current-smokers.  
To validate these observations in a larger NSCLC cohort, mutations in TCGA 
LUAD and LUSC samples were temporally dissected (16). Consistent with our M-seq 
analyses, both TCGA LUAD and LUSC smokers and ex-smokers exhibited a 
decrease in the proportion of C>A transversions in late mutations (Fig. 3B; LUAD 
current-smokers P<0.0001; ex-smokers P<0.0001; never-smokers P=0.147; LUSC 
current-smokers P=0.003; ex-smokers P<0.0001; never-smokers P=0.673). Similarly, 
the least pronounced decrease was observed in LUSC current-smokers; 25% of LUSC 
displayed no decrease in C>A transversions, compared to less than 10% in LUAD. 
The mutational footprint of smoking exhibits a strand bias with C>A transversions 
accumulating preferentially on the transcribed strand (10, 12). Both LUAD and LUSC 
ex-smokers revealed a statistically significant decrease in strand bias (10, 12) in late 
compared to early C>A transversions (LUAD P = 0.00354; LUSC P = 0.046), 
consistent with smoking having left a footprint on these genomes but no longer being 
active. Conversely, no statistically significant difference was observed between early 
and late mutations in current-smokers (LUAD P = 0.23; LUSC P = 0.22).  
In the majority of M-seq tumors, the decreased proportion of C>A mutations 
was accompanied by an increase in C>T and C>G mutations at TpC sites, indicative 
of APOBEC cytidine deaminase activity (13-15). Mutations consistent with 
APOBEC-mediated mutagenesis were more pronounced on the branches compared to 
the trunk in 4/5 LUAD M-seq samples (Fig. 3C). On average 1931% (88-431%) of 
non-silent branch mutations occurred in an APOBEC mutation context compared to 
811% (57--136%) of truncal non-silent mutations. Branched driver mutations 
PIK3CA, EP300, TGFBR1 and AKAP9 harbored mutations in an APOBEC context 
indicating a possible functional impact of APOBEC activity upon subclonal 
expansion. Likewise, TCGA LUAD tumors with detectable APOBEC mutational 
signatures showed significant enrichment in late compared to early APOBEC 
mutations (fig. S12, P <0.001) and 1820% of subclonal driver mutations were found 
to occur in an APOBEC context, compared to 911% of clonal driver mutations.  
However, for TCGA LUSC tumors with detectable APOBEC mutational signatures, 
temporal dissection of APOBEC mutations did not reveal such a clear trend (fig. 
S12), indicating potential differences in the temporal dynamics of APOBEC mediated 
mutagenesis between histological subtypes. In addition to temporal heterogeneity, 
spatial heterogeneity in both the proportion of APOBEC associated mutations (Fig 
3D,E), as well as APOBEC mRNA expression was observed in the M-seq tumors 
(fig. S13).   
To gain a deeper understanding of NSCLC evolution, we focused on the two 
tumors with high coverage M-seq WGS  and temporally placed the genomic 
instability processes relative to the emergence of the most-recent common ancestor 
(Fig. 4). In L002, a current-smoker, tobacco carcinogens played a significant role 
early in tumor development, with C>A transversions representing 39% of truncal 
mutations (Fig 4A). Early mutations included multiple driver genes, such as TP53 and 
CHD8. Upon diversification into a LUAD subclone and a LUSC subclone, copy 
number alterations (fig. S7) and driver mutations were acquired independently in both 
subclones, such as a stopgain mutation in the tumor suppressor gene FAT1 on the 
LUSC branch, and mutations affecting TGFBR1, ZFHX4, ARHGAP35 and PTPRD in 
the LUAD region. APOBEC-associated mutations were elevated specifically in the 
LUAD region, including the driver mutations in TGFBR1 and PTPRD, and the 
highest APOBEC3B mRNA expression was detected in this region (fig. S13). 
L008 also revealed truncal C>A transversions and spatial heterogeneity in 
APOBEC enrichment, with a more pronounced APOBEC signature in the tumor of 
the middle lobe compared to the upper lobe (Fig 4B). In L008 we gained further 
temporal resolution by exploring the mutations before and after the truncal genome-
doubling event, revealing a tobacco smoke signature of C>A transversions in over 
30% of truncal mutations both before and after doubling, and only in 21% and 9% of 
heterogeneous mutations in the two regions R1 and R3 from separate lobes of the 
lung. Since L008 ceased smoking over 20 years prior to surgery (table S1), these data 
suggest the genome-doubling event occurred within a smoking carcinogenic context 
over 20 years ago. Similarly, the genome-doubling event in ex-smoker L001 also 
appeared to occur prior to smoking cessation over 20 years prior to surgery (fig S14). 
These data suggest a prolonged tumor latency period following genome doubling 
prior to clinical detection in NSCLC.  
Through sequencing multiple surgically resected tumor regions we were able 
to unravel both the extent of genomic heterogeneity and the evolutionary history of 
seven NSCLCs. Unlike clear cell renal cell carcinoma (ccRCC)(27, 28), we find that 
known driver mutations typically occur early in NSCLC development and the 
majority of high confidence driver events are fully clonal, conceivably explaining the 
progression free survival benefits associated with NSCLC oncogenic driver targeting 
(29).  However, like ccRCC(27, 28), heterogeneous driver mutations and/or recurrent 
copy number aberrations were present in all tumors and many heterogeneous 
mutations gave the “illusion of clonality” being present in all cells from certain 
regions but undetectable within other regions. Notably, although our multi-regional 
sampling approach allowed us to evaluate spatial heterogeneity, we estimate only a 
small part of the entire tumor was sampled (on average <5%), suggesting we might be 
underestimating the full extent of heterogeneity in these tumors.  
Conceivably, intra-tumor heterogeneity may compromise the ability of a 
single biopsy to define all driver events comprehensively for optimal tumor control. 
For instance, L008 presented with an activating BRAF (G469A) mutation (30) in all 
regions and an activating PIK3CA (E542K) mutation (31) only in region R3. Thus, a 
biopsy taken from R3 might suggest treatment with an inhibitor of the PI3K/mTOR 
signaling axis and combination therapy. Conversely, a single biopsy from any other 
region would suggest treatment with a BRAF inhibitor, for which the tumor cells 
from R3 might be resistant due to the PIK3CA mutation (32). 
Our study also sheds light on the divergent genomic instability processes 
involved in NSCLC evolution and their dynamics over time. Evidence for spatial 
diversity in genomic instability processes suggests that opportunities to exploit such 
mechanisms therapeutically may be limited in this disease(33). In three tumors we 
detected genome-doubling events occurring prior to subclonal diversification but after 
acquisition of driver mutations, consistent with findings in colorectal cancer that 
genome doubling may accelerate cancer genome evolution (34). The relationship of 
chromosomal instability with drug resistance and early tumor recurrence (35, 36) 
suggest targeting truncal driver events may be compromised by the initiation of 
chromosomal instability later in tumor evolution. These results, coupled with the 
observation that NSCLC tumors may have prolonged latency periods, support 
continued efforts to optimize methods for earlier detection 
Unexpectedly, after detectable subclonal diversification, we find that even in 
tumors that are continuously subject to the mutagenic insults of tobacco smoke, an 
additional genomic instability process, such as APOBEC-mediated mutagenesis, often 
contributes to tumor progression. A large proportion of subclonal driver mutations 
were found to occur in an APOBEC context suggesting the differences in mutation 
spectra over time and space may reflect the activity of the process generating the 
mutations as well as the selective advantage of the acquired mutations.  
The presence of subclonal, regionally separated driver events coupled with the 
relentless and dynamic nature of genomic instability processes observed in this study, 
highlight the therapeutic challenges associated with NSCLC. Engaging an adaptable 
immune system may present a tractable approach to manage the dynamic complexity 
in NSCLC(37). Longitudinal studies will be required to decipher drivers of subclonal 
expansion, identify the origins of subclones contributing to metastatic recurrence and 




Fig. 1. Intratumor heterogeneity of somatic mutations.  
A) Heatmaps show the regional distribution of all non-silent mutations; presence 
(blue) or absence (grey) of each mutation is indicated for every tumor region. 
Cartoons depict the location of each tumor. Column next to heatmap shows the 
intratumor heterogeneity; mutation present in all regions (blue), in more than one, but 
not all (yellow) or in one region (red). Mutations are ordered on tumor driver category 
with categories 1-3 indicated in the right column in black, dark grey and light grey 
respectively (details in table S3). Total number of non-silent mutations (n) is provided 
for each tumor. In L001, * this mutation is additional to the germ-line MEN1 
mutation.  
B) 2D-dirichlet plots show the cancer cell fraction of the mutations in all regions of 
tumors L004; increasing intensity of red indicates the location of a high posterior 
probability of a cluster. In region R5 the majority of heterogenous mutations are 
subclonal and a cluster of mutations with a cancer cell fraction below 1 can be 
observed. 
 
Fig. 2. Intratumor heterogeneity of chromosomal alterations. 
A) Distribution of potential tumor driver copy number alterations is indicated for each 
tumor region. The upper heatmaps show the regional distribution of recurrently 
amplified (left) or deleted (right) chromosomal segments based on TCGA LUAD 
data, and the lower heatmaps show the regional distribution of recurrently amplified 
or deleted chromosomal segments based on TCGA LUSC data. For each region gain 
(red) and loss (blue) was determined relative to the mean ploidy.  
B) Circos plots depicting inter- and intrachromosomal translocations as well as 
deletions and insertions for regions R1 and R3 for L002 (upper) and L008 (lower); 
shared events are indicated in blue, events private to region R1 are indicated in red 
and private to region R3 in green. The outer circle represent the integer copy number 
data for R1 and the inner circle for R3 for each tumor sample, copy number segments 
with an integer value greater than mean ploidy are in red and those less than mean 
ploidy in blue.  
 
Fig. 3. Temporal and spatial dissection of mutation spectra in LUAD and LUSC 
samples.  
A) Pie chart showing the fraction of early mutations (trunk) and late mutations 
(branch) accounted for by each of the six mutation types in all M-seq samples.  
B) Beeswarm plots showing the fraction of early mutations and late mutations 
accounted for by each of the six mutation types in every TCGA ex-smoker or current-
smoker with both early and late mutations.  Significance is indicated.  
C) Barplot showing APOBEC mutation enrichment odds ratio for early (trunk, blue 
bars) and late (branch, red bars) mutations for M-seq samples. The APOBEC 
signature encompasses C>T and C>G mutations in a TpC context (16). 95% 
confidence intervals for Fisher’s exact test are indicated.  
D,E) Stacked barplots showing three mutation types (C>A; C>G and C>T) at all 
sixteen possible trinucleotide contexts for L002 (D) and L008 (E). For both samples, 
trunk mutations and branch mutations from two regions are depicted. 
Fig. 4. A model of the evolutionary history of NSCLC. 
A, B) Evolutionary histories of L002 (A) and L008 (B) are depicted. Genomic 
instability processes defining NSCLC evolution have been placed on their 
phylogenetic trees. Driver mutations occurring in an APOBEC context are highlighted 
with a blue dashed box, and those occurring in a smoking context with a grey dashed 
box. In each case, the timing of genome doubling events is indicated with an arrow.  
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